A Study to Evaluate Opevesostat (MK-5684) in Male Participants With Moderate Hepatic Impairment (MK-5684-009)
Completed · Phase 1
Conditions studied: Hepatic Impairment, Healthy Participants
In brief
Researchers have designed a study medicine called opevesostat as a new way to treat prostate cancer. The purpose of this study is to learn what happens to opevesostat in a person's body over time (a pharmacokinetic \[PK\] study). Researchers will compare what happens to opevesostat in the body when it is given to healthy participants and participants with moderate hepatic (liver) impairment.
Key facts
- Study ID
- NCT06860243
- Run by
- Merck Sharp & Dohme LLC
- People needed
- 16
- Starts
- 2025-05-13
- Expected to finish
- 2026-02-19
- Last updated by the study team
- 2026-02-24
Who can join
Age: 18 and older. Sex: male. Healthy volunteers: accepted.
Where it is running
- Clinical Pharmacology of Miami ( Site 0002) — Miami, Florida, United States
- Texas Liver Institute ( Site 0001) — San Antonio, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.